Table 1. Clinical characteristics of 210 patients who underwent autologous peripheral blood stem cell transplantation.

|  |  |
| --- | --- |
| **Patient characteristics** | **Number (%)** |
| Total | 210 (100%) |
| Age, years – Median (range)Age Groups18-2930-3940-4950-59≥ 60 | 43 (19-65)51 (24.3%)34 (16.2%)45 (21.4%)57 (27.1%)23 (11.0%) |
| Gender Malefemale | 87 (41.4 %)123 (58.6 %) |
| Underlying disease LymphomaMultiple myeloma | 115 (54.8 %)95 (45.2 %) |
| Disease status before transplantComplete remissionPartial remissionStable diseaseunknown | 34 (16.1 %)147 (70.0 %)4 (2.0 %)25 (11.9 %) |
| CMV status before transplantIgG positive IgM positive  | 205 (97.6%)10 (4.8 %) |
| CMV prophylaxis givenAcyclovirValacyclovir Unknown | 198 (94.3%)11 (5.2%)1 (0.5%) |
| Conditioning regimenLymphoma patientsBEAMTEAMMultiple myeloma patientsMelphalan | 111 (96.5%)4 (3.5%)95 (100%) |
| Median time to engraftment, days (range)Median neutrophil engraftment Median platelet engraftment  | 10 (7-15)16 (7-47) |
| MortalityOverallDay 100 | 50 (23.8%)6 (2.9%) |

Abbreviations: CMV, Cytomegalovirus; BEAM, BCNU, Etoposide, Cytarabine, Melphalan; TEAM, Thiotepa, Etoposide, Cytarabine, Melphalan